DarioHealth Corp. DRIO
Medical/Dental Instruments · data as of November 13, 2026
DarioHealth Corp. (DRIO) is a healthcare company listed in the US with a market value of about $14M. In the twelve months to September 30, 2026 it had revenue of $21M and net income of -$34M, a net margin of -159.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 24% a year, a 5-year average ROIC of -49%.
About DarioHealth
DarioHealth is listed in the US and classified in medical/dental instruments. Revenue went from $51000 in 2014 to $22M in 2025, growth of about 73.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 237% over three years (dilution for shareholders). It spends 62% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21M | $22M | $27M | $20M | $28M | $21M | $8M | $8M | $7M | $5M | $3M |
| Net income | -$34M | -$42M | -$43M | -$59M | -$62M | -$77M | -$29M | -$18M | -$18M | -$16M | -$11M |
| Free cash flow | -$24M | -$26M | -$39M | -$31M | -$48M | -$51M | -$18M | -$16M | -$12M | -$11M | -$9M |
| EPS (diluted) | $-2.28 | $3.37 | $4.09 | $12.87 | $16.93 | $27.13 | $26.73 | $53.33 | $104.20 | $218.67 | $278.67 |
| Net margin | -159.9% | -186.6% | -158.1% | -292.0% | -224.9% | -374.2% | -388.7% | -234.6% | -240.8% | -304.5% | -388.4% |
| ROIC | — | -29.0% | -54.1% | -50.6% | -41.5% | -70.4% | -82.4% | -71.1% | -156.6% | -289.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $8.20, 551% above the current price; targets range from $5.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-2.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does DarioHealth pay a dividend?
Not currently.
Is DarioHealth a good stock to buy?
We do not give buy or sell advice. DarioHealth scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.